Oncogenic KRAS drives metabolic reprogramming in tumor cells by increasing aerobic glycolysis, and recent studies showed that subtypes of PDAC cells with distinct metabolite levels associated with glycolysis, lipogenesis, and redox pathways, confirmed at the transcriptional level. Here, KRAS is linked to neoplasm.